Mechanistically, the antitumor efficacy of PD-1-laIL-2 relied on intratumoral CD8+ T cells, particularly PD-1+TIM3+ tumor-infiltrating lymphocytes (TILs).30 The gene discussed is CD8A; the disease is neoplasm.